INDGN/SE/2026-27/06

April 29, 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India. Trading symbol: INDGN

Dear Sir / Madam,

Sub: Intimation of Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held today, i.e., April 29, 2026, has:

Approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with Auditor's Report thereon. The Financial Results along with the Auditors' Report with an unmodified opinion are enclosed herewith.
Recommended a final dividend of Rs. 2.25/- per equity share of Rs. 2/- each of the Company for the financial year ended March 31, 2026. The Company will pay the proposed final dividend within 30 days after approval of the shareholders in the ensuing Annual General Meeting (AGM). The record date for the purpose of determining shareholders eligible to receive dividend and the date of AGM, shall be intimated in due course.
Approved allotment under ESOP Scheme 2020 and RSU Scheme 2020.
Approved amendments to the policies under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015

i. Policy for determining Material Subsidiary;
ii. Whistle Blower Policy;
iii. Policy for procedure for inquiry in case of leak of unpublished price sensitive information/ breach of the code;
iv. Code of conduct for prevention of insider trading and code of practices and procedures for fair disclosure of unpublished price sensitive information;
v. Policy on materiality of related party transactions and on dealing with related party transactions;
vi. Nomination and Remuneration Policy;
vii. Policy on Evaluation of the performance of the Board of Directors;

Indegene

Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy

Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777

www.indegene.com

CIN: L73100KA1998PLC102040

viii. Policy on Board diversity;
ix. Policy on Criteria for making payment to Non-executive Directors (NeDs);
x. Policy on Code of conduct for Directors and Senior Management Personnel;
xi. Policy for determination of materiality for disclosure of events or information;
xii. Terms and Conditions of Independent Directors;
xiii. Policy for familiarization program for Independent Directors;
xiv. Corporate Social Responsibility Policy;
xv. Risk Management Policy;
xvi. Dividend Distribution Policy
xvii. Prevention of Sexual Harassment Policy;
xviii. Indegene Policy On Interaction with Investors / Analysts and Silent Period
xix. Policy on Preservation of Records Archival Policy on Website

The meeting of the Board of Directors commenced at 5:30 P.M. IST and concluded at 7:10 P.M. IST.

The above information is being made available on the website of the Company https://www.indegene.com/.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

SRISHTI
RAMESH
KAUSHIK

Srtshti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: A/a

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High
Grounds, Bengaluru - 560 001
Karnataka, India
Tel: +91 (80) 6188 6000
Fax: +91 (80) 6188 6011

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer ‘Other Matters’ section below), which were subject to limited review by us, both included in the accompanying “Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026 of INDEGENE LIMITED” (the “Parent Company”) and its subsidiaries (the Parent Company and its subsidiaries together referred to as the “Group”), and its share of the net profit after tax and other comprehensive income for the quarter and year ended March 31, 2026, (the “Statement”), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “LODR Regulations”).

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the separate financial statements / financial information of subsidiaries, associates and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:

(i) includes the financial results of the entities as mentioned in Annexure I to this review and audit report.

(ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor’s Responsibilities section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements/ interim consolidated financial information. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Page 2 of 7

Deloitte Haskins & Sells

Auditor’s Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026.

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the

Page 3 of 7

Deloitte Haskins & Sells

Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial Information of, entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such branches or entities included in the Annual Consolidated Financial Results of which we are the independent auditors. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026.

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as mentioned in Annexure I to this Report.

Page 4 of 7

Deloitte Haskins & Sells

Other Matters

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
We did not audit the financial statements / financial information of 1 subsidiary and 8 step down subsidiaries included in the consolidated financial results, whose financial statements / financial information reflect total assets of Rs. 991 million as at March 31, 2026 and total revenues of Rs. 364 million and Rs. 980 million for the quarter and year ended March 31, 2026 respectively, total net profit after tax of Rs. 19 million and Rs. 57 million for the quarter and year ended March 31, 2026 respectively and other comprehensive income of Rs. 219 million and Rs. 62 million for the quarter and year ended March 31, 2026 respectively and net cash flows of Rs. 385 million for the year ended March 31, 2026, as considered in the Statement. These financial statements/ financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial statements/financial information. In our opinion, and according to the information and explanations given to us by the Board of Directors, these financial statements / financial information are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial statements/ financial information certified by the Board of the Directors.

Reporting on comparatives reviewed/ audited by the predecessor auditor

The consolidated financial statements/consolidated financial results of the Parent Company for the quarter and year ended March 31, 2025 included in the Statement, were reviewed/audited by the predecessor auditor who expressed an unmodified conclusion/opinion on those statements/results on April 28, 2025.

Our report on the statement is not modified in respect of this matter.

For Deloitte Haskins & Sells
Chartered Accountants
Firm's Registration No. 008072S

Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920GEVRUE1861

Place: Bengaluru
Date: April 29, 2026

Page 5 of 7

Deloitte Haskins & Sells

Annexure I to Independent Auditor's Report on Audit of Annual Consolidated Financial Results and Review of quarterly consolidated financial results.

The Consolidated Unaudited Financial Results for the quarter and year ended March 31, 2026 include financial results of the following companies:

Sr. No.	Company Name	Category	Country of Incorporation
1	Indegene Limited	Parent Company	India
2	ILSL Holdings Inc.	Wholly Owned Subsidiary	USA
3	Indegene Inc.	Step Down Subsidiary	USA
4	Services Indegene Aptilon Inc. (merged with Trilogy Writing & Consulting Inc. to form Indegene Healthcare Canada Inc. w.e.f January 1, 2026)	Step Down Subsidiary	Canada
5	DT Associates Research and Consulting Services Ltd	Step Down Subsidiary	England
6	DT Associates Research and Consulting Inc.	Step Down Subsidiary	USA
7	Cult Health LLC	Step Down Subsidiary	USA
8	Indegene Japan LLC	Step Down Subsidiary	Japan
9	Indegene Healthcare Mexico S DE RL DE CV	Wholly Owned Subsidiary	Mexico
10	Indegene Ireland Limited	Wholly Owned Subsidiary	Ireland
11	Indegene Healthcare Germany GmbH	Step Down Subsidiary	Germany
12	Indegene Fareast Pte Ltd	Step Down Subsidiary	Singapore
13	Indegene Europe LLC	Step Down Subsidiary	Switzerland
14	Indegene Lifesystems Consulting (Shanghai) Co. Ltd.	Step Down Subsidiary	China
15	Indegene Healthcare UK Limited	Step Down Subsidiary	England
16	Trilogy Writing & Consulting GmbH	Step Down Subsidiary	Germany
17	Trilogy Writing & Consulting Limited	Step Down Subsidiary	England
18	Trilogy Writing & Consulting Inc.	Step Down Subsidiary	USA
19	Trilogy Writing & Consulting Inc. (erstwhile Trilogy Writing and Consulting ULC (Canada) renamed w.e.f December 22, 2025 and merged with Services Indegene Aptilon Inc. to form Indegene Healthcare Canada Inc. w.e.f January 1, 2026)	Step Down Subsidiary	Canada
20	Indegene Spain S.L.U	Step Down Subsidiary	Spain
21	MJL Communications Group Ltd	Step Down Subsidiary	England
22	MJL Advertising Limited	Step Down Subsidiary	England
23	BioPharm Parent Holding, Inc	Step Down Subsidiary	USA
24	BioPharm Communications LLC	Step Down Subsidiary	USA
25	Addressable Health LLC	Step Down Subsidiary	USA

Page 6 of 7

Deloitte
Haskins & Sells

Sr. No.	Company Name	Category	Country of Incorporation
26	Warn and Co Limited	Step Down Subsidiary	England
27	Cake Kommunikations Holding GmbH	Step Down Subsidiary	Austria
28	Cake Kommunikations GmbH (DE)	Step Down Subsidiary	Germany
29	Cake Kommunikations AG (Switzerland)	Step Down Subsidiary	Switzerland
30	Cake Kommunikations GmbH (AT)	Step Down Subsidiary	Austria
31	Indegene Healthcare Canada Inc. (formed by merger of Services Indegene Aptilon Inc. and Trilogy Writing & Consulting Inc. w.e.f January 1, 2026)	Step Down Subsidiary	Canada

Page 7 of 7

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Year ended
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Unaudited (Refer Note 2)	Unaudited	Unaudited (Refer Note 2)	Audited	Audited
1	Income
	(a) Revenue from operations	10,034	9,421	7,556	35,105	28,393
	(b) Other income (net)	108	194	256	720	1,072
	Total income	10,142	9,615	7,812	35,825	29,465
2	Expenses
	(a) Employee benefits expense	6,324	5,680	4,851	21,977	18,152
	(b) Finance costs	72	46	31	193	220
	(c) Depreciation and amortisation expense	418	396	207	1,264	802
	(d) Other expenses	2,074	2,146	1,230	6,938	4,898
	Total expenses	8,888	8,268	6,319	30,372	24,072
3	Profit before exceptional item and tax (1-2)	1,254	1,347	1,493	5,453	5,393
4	Exceptional items (net) (refer note 10)	(203)	-	-	(203)	-
5	Profit before tax (3+4)	1,051	1,347	1,493	5,250	5,393
6	Tax expense
	- Current tax	226	874	438	1,763	1,491
	- Deferred tax	28	(556)	(121)	(524)	(165)
	Total tax expense	254	318	317	1,239	1,326
7	Profit for the period/year (5-6)	797	1,029	1,176	4,011	4,067
8	Other Comprehensive Income (OCI), net of taxes
	Items that will not be reclassified subsequently to the statement of profit or loss:
	Remeasurement of defined benefit obligation	(1)	6	(39)	41	(21)
	Deferred tax relating to items that will not be reclassified to profit and loss	1	(2)	10	(10)	5
	Items that will be reclassified subsequently to profit or loss:
	Exchange differences on translating the financial statements of foreign operations	599	189	55	1,412	272
	Net change in fair value of forward contracts designated as cash flow hedges	(66)	-	-	(66)	-
	Deferred tax relating to items that will be classified to profit and loss	17	-	-	17	-
9	Total Other Comprehensive Income for the period/year (net of tax)	550	193	26	1,394	256
	Total Comprehensive Income for the period/year (7+8)	1,347	1,222	1,202	5,405	4,323
	Profit for the period/year attributable to:
	Owners of the Parent	797	1,029	1,176	4,011	4,067
	Other Comprehensive Income for the period/year attributable to:
	Owners of the Parent	550	193	26	1,394	256
	Total Comprehensive Income for the period/year attributable to
10	Paid-up equity share capital (Face value of ₹ 2 each)	481	480	479	481	479
11	Other equity				30,906	25,677
12	Earnings per equity share (face value of ₹ 2 each)*
	(a) Basic (in ₹)	3.32	4.29	4.91	16.72	17.15
	(b) Diluted (in ₹)	3.30	4.26	4.88	16.62	17.02

*Earnings per share is not annualised for quarter and nine months ended.

See accompanying notes to the Consolidated Financial Results

E
10
INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Statement of Consolidated Assets and Liabilities

(All amounts in ₹ millions)

| Particulars | As at
31 March 2026 | As at
31 March 2025 |
| --- | --- | --- |
| | Audited | Audited |
| A ASSETS | | |
| I Non-current assets | | |
| (a) Property, plant and equipment | 586 | 402 |
| (b) Capital work-in-progress | 118 | 36 |
| (c) Right-of-use assets | 1,354 | 947 |
| (d) Goodwill | 11,343 | 3,565 |
| (e) Other intangible assets | 4,833 | 1,862 |
| (f) Financial assets | | |
| (i) Other financial assets | 804 | 133 |
| (g) Deferred tax assets (net) | 768 | 898 |
| (h) Non-current tax assets (net) | 172 | 91 |
| (i) Other non-current assets | 41 | 25 |
| Total non current assets | 20,019 | 7,959 |
| II Current assets | | |
| (a) Financial assets | | |
| (i) Investments | 10,995 | 12,897 |
| (ii) Trade receivables | | |
| Billed | 7,702 | 6,322 |
| Unbilled | 2,116 | 1,192 |
| (iii) Cash and cash equivalents | 3,008 | 2,410 |
| (iv) Other bank balances | 811 | 1,336 |
| (v) Other financial assets | 103 | 126 |
| (b) Current tax assets (net) | 65 | - |
| (c) Other current assets | 1,384 | 1,017 |
| Total current assets | 26,184 | 25,300 |
| Total assets | 46,203 | 33,259 |
| B EQUITY AND LIABILITIES | | |
| 1 Equity | | |
| (a) Equity share capital | 481 | 479 |
| (b) Other equity | 30,906 | 25,677 |
| Total equity | 31,387 | 26,156 |
| 2 Liabilities | | |
| I Non-current liabilities | | |
| (a) Financials liabilities | | |
| (i) Lease liabilities | 1,050 | 724 |
| (ii) Other financial liabilities | 2,031 | 149 |
| (b) Provisions | 873 | 585 |
| Total non-current liabilities | 3,954 | 1,458 |
| II Current liabilities | | |
| (a) Financials liabilities | | |
| (i) Lease liabilities | 394 | 292 |
| (ii) Trade payables | | |
| Total outstanding dues of micro enterprises and small enterprises and | 26 | 17 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,781 | 917 |
| (iii) Other financial liabilities | 3,055 | 1,151 |
| (b) Other current liabilities | 4,325 | 2,510 |
| (c) Provisions | 798 | 677 |
| (d) Current tax liabilities (net) | 483 | 81 |
| Total current liabilities | 10,862 | 5,645 |
| Total liabilities | 14,816 | 7,103 |
| Total equity and liabilities | 46,203 | 33,259 |

See accompanying notes to the Consolidated Financial Results

INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Statement of Consolidated Cash Flow

(All amounts in ₹ millions)

Particulars	Year ended
	31 March 2026	31 March 2025
	Audited	Audited
A. Cash flows from operating activities
Profit before tax for the period	5,250	5,393
Adjustments to reconcile profit for the year to net cash generated from operating activities:
Depreciation and amortisation expense	1,265	802
Finance costs	159	194
Gain due to change in contingent consideration	-	(162)
Exceptional items - Provision for litigation expenses	203	-
Interest income and dividend income	(363)	(501)
Loss allowance on loan	-	135
Net gain on disposal / fair valuation of investments	(300)	(292)
Gain on termination of lease	(9)	-
Loss on sale of fixed assets	(1)	-
Bad debts written off	8	-
Expected credit loss provision / (reversal) on trade receivables and advances	-	18
Equity settled share based payment expense	256	174
Effect of exchange loss / (gain) on restatement	54	17
Operating profit before working capital changes	6,522	5,778
Movements in working capital:
(Increase)/decrease in trade receivables	35	(820)
(Increase)/ decrease in loans and advances and other assets	(231)	343
Increase in liabilities	1,437	611
Increase in provisions	221	107
Cash generated from operating activities	7,984	6,019
Income tax paid (net)	(1,476)	(1,600)
Net cash generated from operating activities (A)	6,508	4,419
B. Cash flows from investing activities
Purchase of property, plant and equipment	(443)	(300)
Interest received	126	486
Payment for acquisition of business, net of cash acquired	(7,235)	(1,113)
Purchase of Investments accounted for using the FVTPL	(35,616)	(52,572)
Redemption of Investments	38,090	47,932
Investment in fixed deposit	(3,663)	(18,168)
Redemption / maturity of fixed deposit	3,617	16,908
Net cash used in investing activities (B)	(5,124)	(6,827)
C. Cash flows from financing activities
Proceeds from fresh issue of equity shares (net of share issue expense)	53	7,327
Interest and finance charges paid	-	(103)
Payment of lease liabilities	(399)	(318)
Dividend Paid	(480)	-
Repayment of borrowings	-	(4,031)
Net cash generated / (used) in from financing activities (C)	(826)	2,875
Net increase in cash and cash equivalents (A+B+C)	558	467
Cash and cash equivalents at the beginning of the year	2,410	1,886
Effect of exchange differences on translation of foreign currency cash and cash equivalents	40	57
Cash and cash equivalents at the end of the year	3,008	2,410

For the purpose of the statement of cash flow, cash and cash equivalents comprise the following:

Particulars	As at
	31 March 2026	31 March 2025
	Audited	Audited
Cash in hand	-	-
Balances with banks:
- In current accounts	2,258	1,503
- In deposit accounts	750	907
Total	3,008	2,410

See accompanying notes to the Consolidated Financial Results

10
INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

The above Consolidated Financial Results of Indegene Limited (the Company' or 'the Parent' or 'the Holding Company') together with its affiliates (collectively 'the Group'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. *** in the financial information denote amounts less than ₹ 0.50 million.
The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 April 2026 and approved by the Board of Directors at its meeting held on 29 April 2026. The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and published unaudited year to date figures up to the end of the third quarter of the current and previous financial year respectively, which were subject to limited review.
The Consolidated Financial Results for the quarter and year ended 31 March 2026, are available on the National Stock Exchange of India Limited (URL: www.nssindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
During the year ended 31 March 2025, the Company had completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹ 2 each at an issue price of ₹452 per share (Issue price of ₹422, including a share premium of ₹420 per share, for employee quota towards fresh issue), comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company has received an amount of ₹7,246(1) (net of Company's share of IPO expenses of ₹354, retained in the Public Offer Account to the extent unpaid) from the proceeds of the fresh issue. Out of the Company's shares of IPO expenses ₹319 has been adjusted to securities premium.

The utilization of IPO proceeds of ₹7,246(1) is summarized below:

Particulars	Amount to be utilised as per offer document (1)	Amount utilized up to 31 March 2026	Amount unutilized as of 31 March 2026
Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc. (2)	3,950	3,950	-
Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries	644	577	67
Technology, Cybersecurity and Cloud infrastructure related cost (1)	350	253	97
General corporate purposes and inorganic growth	2,302	2,294	8
Total utilisation of funds	7,246	7,074	172

(1) Pursuant to the Special Resolution passed at the Shareholders' Meeting held on 12 August 2025, the Company has revised the objects as per offer document. As per the revised objects, an amount of ₹37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings, Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment. Further, an amount of ₹350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services, productivity tools, cybersecurity and support services availed by the Company and Indegene Inc. Further, the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026. The unutilized amount of ₹2 has been transferred to the net IPO proceeds, thereby increasing it from ₹7,244 to ₹7,246 and earmarked for funding capital expenditure requirements at the Company's office premises.

(2) During the year ended 31 March 2025, the Company has repaid loan of USD 47.20 Million (₹3,950) outstanding in the books of ILSL Holdings Inc. (material subsidiary), in line with Object 1 of the offer document. The amount of ₹37 utilised over and above the maximum amount specified as per the original amount as per offer document of ₹3,913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment. The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference.

Out of the net proceeds which were unutilised as at 31 March 2026, ₹151 (31 March 2025: ₹980) are temporarily invested in fixed deposits, ₹19 (31 March 2025: ₹41) is held in the Company's monitoring account, while the balance amount of ₹2 (31 March 2025: Nil) is held in the public offer account.

During the year ended 31 March 2026, 613,772 options have been granted under Employee Restricted Stock Unit plan 2020 ('RSU 2020'), 318,251 options have been granted under Employee Stock Option Plan 2020 ('ESOP 2020') and 56,462 options have been granted under Company Share Option Plan 2022 ('CSOP 2022') to the eligible employee of the Company. 670,418 options under RSU 2020 plan, 215,192 options under ESOP 2020 plan and 7,782 options under ESOP 2020 plan have been exercised during the year.
Acquisition of MJL Communications Group Ltd:

On 25 March 2025, the Group had obtained control of MJL Communications Group Ltd ('MJL') by acquiring 100% of its shares. The acquisition was consummated for a consideration of ₹ 411 which includes earmost payment of ₹ 150. The contingent consideration is based on the performance of MJL during the fiscal year beginning 01 April 2025 and ending 31 March 2027 and range of contingent consideration payable is between Nil to ₹ 172. The Group has concluded that the acquisition is business and did the provisional PPA for the same during year ended 31 March 2025, which was finalised during the year ended 31 March 2026.

The fair value of net assets acquired on the acquisition date as a part of the transaction amounted to ₹ 98. The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to ₹ 174 and goodwill aggregating to ₹ 139.

10
INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

7. Acquisition of Biopharm Parent Holdings Inc.:

On 30 September 2025, the Group has entered into a stock purchase agreement with BioPharm Parent Holding Inc., ('BioPharm') and Engage Acquisition Corp. ("Seller") to acquire 100% interest in BioPharm a specialized marketing services agency, part of Omnicom Health Group, for an aggregate purchase consideration of ₹ 8,821 million (USD 99.77 million), including deferred and contingent earn out consideration.

Further On 01 October 2025, the Group had obtained control of BioPharm. The Company is a full-service, healthcare marketing agency which helps brand teams at pharmaceutical and biotech companies execute customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. The acquisition was consummated for a consideration of ₹ 8,821 million which includes earnout payment of ₹ 2,134 million. The contingent consideration is based on the performance of Biopharm during the fiscal year 2025 and 2026 and range of contingent consideration payable is between Nil to ₹ 707 million (USD 8 million) for the year 2025 and Nil to ₹ 1,680 (USD 19 million) for the year 2026. The Group believes that the acquisition will strengthen the Group's commercialization portfolio by integrating advanced AI and digital advertising technologies, enabling pharmaceutical companies to achieve more precise, scalable and measurable marketing outcomes. The Group has concluded that the acquired set is a business.

The following table presents the allocation of purchase price:

Particulars	Acquired's carrying amount	Fair value adjustments	Purchase price allocated
Assets
Net assets taken over [I]	234	-	234
Identifiable intangibles assets
Customer relationship		1,594	1,594
Customer Contracts		190	190
Brand		85	85
Intellectual Property		817	817
Non-compete agreement		187	187
Deferred tax liability on intangible assets		(715)	(715)
Total identifiable intangible assets acquired [II]			2,158
Total [I + II]			2,392
Goodwill			6,429
Total purchase price			8,821

The fair value of net assets acquired including the identified intangibles as on the acquisition date as a part of the transaction amounted to ₹ 2,392. The excess of purchase consideration over the fair value of net assets acquired has been attributed towards goodwill. The goodwill of ₹ 6,429 comprises value of acquired workforce and expected synergies arising from the acquisition. Net assets acquired included ₹ 222, ₹ 620, ₹ 984, ₹ 60, ₹ 557 and ₹ 1095 of Cash and cash equivalents, trade receivable, unbilled revenue, other assets, accounts payable and other liabilities respectively. None of the trade receivables have been impaired and it is expected that its full contractual amount can be collected. Goodwill is allocated to Enterprise Commercial Solutions segment and is not deductible for income tax purposes of respective country tax laws. The aggregate cost incurred for the acquisition is ₹ 123.

If the acquisition had occurred on 01 April 2025, management estimates that the annual consolidated revenue for the Group would have been ₹ 38,343 and the annual profit before taxes for the year for the Group would have been ₹ 6,369. The pro-forma amounts are not necessarily indicative of the results that would have occurred if the acquisitions had occurred on date indicated or that may result in the future.

8. Acquisition of Warn & Co Limited:

On 16 October 2025, the Group acquired 100% interest in Warn & Co Limited, a specialized transformation consulting firm, for an aggregate purchase consideration of ₹ 464 (GBP 3.91 million), including an earnout component. The acquisition has been accounted for as a business combination under Ind AS 103. The fair value of net assets acquired on the acquisition date as part of the transaction amounted to ₹ 219 (GBP 1.84 million). The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to ₹ 136 (GBP 1.14) and goodwill aggregating to ₹ 109 (GBP 0.93 million).

9. Acquisition of Cake Kommunikations Holdings GmbH:

On 10 November 2025, the Group had entered into a stock purchase agreement to acquire Cake Kommunikations Holdings GmbH (an SPV created to hold 70% in Cake Kommunikations GmbH (AT), 100% in CAKE Kommunikations GmbH (DE) and 100% in CAKE Kommunikations AG (Switzerland)) and 30% in Cake Kommunikations GmbH (AT) from Werner Hinterberger [Collectively 'Cake Group'], an advertising agency specialized in healthcare and pharmaceutical communication, for an aggregate purchase consideration of ₹ 904 (EUR 8.9 million), including earnout consideration. The Group believes that the acquisition will enable the Group to expand its healthcare marketing and communication capabilities in Europe, specifically targeting the DACH region (Germany, Austria and Switzerland), thereby strengthening the Group's footprint by offering specialized, high-touch marketing services.

Further on 30 January 2026, the Group had obtained control of Cake Group and has carried out the provisional purchase price allocation for the acquisition during the quarter ended 31 March 2026 and the same will be finalised within the measurement period but in no event later than one year following the date of acquisition (30 January 2026).

A
12
INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

10. Exceptional item: Litigation expenses

During the year 2020-21, Indegene Inc. (a subsidiary of the Company) was named in a class action lawsuit filed in the U.S. District Court of New Jersey, alleging non-compliance with the Telephone Consumer Protection Act of 1991 ('TCPA') by sending unsolicited fax advertisements without the recipient's prior express invitation or permission.

Plaintiff initiated this matter through the filing of its Class Action Complaint against Indegene, Inc., Indegene Encima Inc., Indegene Wincere Inc., and Indegene Healthcare, LLC (collectively, "Indegene" or "Defendants") seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the sum of USD 500 for each violation, whichever is greater, and that the Court award treble damages of USD 1,500 if the violations are deemed wilful or knowing. Additionally, the Plaintiff seeks the Court award pre-judgment interest and costs, to be determined upon presentation of suitable evidentiary support.

During the year ended 31 March 2026, the matter progressed to mediation and the Group agreed in principle to a mediator-proposed settlement framework providing for a maximum settlement amount of Rs. 417 (USD 4.72 million). The proposed settlement is structured as a claims-made arrangement, whereby the actual outflow is contingent upon valid claims submitted by eligible class members, and unclaimed amounts, if any, revert to the Group. The proposed settlement remains subject to execution of definitive agreements and approval by the Court.

Based on the current status of the proceedings and Group's assessment, supported by external legal advice, the Group has concluded that a present obligation exists and that an outflow of economic resources is probable and can be reliably estimated. Accordingly, the Group has recognised a provision of Rs. 203 (USD 2.30 million), including estimated legal costs, representing best estimate of the expenditure required to settle the obligation as at the reporting date.

On 31 December 2025, Indegene, Inc. and Trilogy Writing and Consulting GmbH, the step-down subsidiaries of the Company, signed a Share Purchase Agreement to acquire 100% equity shares of Trilogy Writing & Consulting Inc. (formerly Trilogy Writing and Consulting ULC), a wholly owned subsidiary of Trilogy Writing and Consulting GmbH, for a cash consideration of EURO 329,014. Subsequently, on 01 January 2026, the Company's step-down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc., both wholly owned by Indegene, Inc. USA, amalgamated to form Indegene Healthcare Canada Inc.

During the current year, the Group realigned its organisation structure by way of sale of investment in DT Associates Research and Consulting Services Limited (subsidiary of ILSL Holding Inc.) and Trilogy Writing and Consulting Limited (subsidiary of Trilogy Writing & Consulting GmbH) to Indegene Healthcare UK Limited (subsidiary of Indegene Ireland Limited) for a consideration of GBP 2,001,000 and GBP 702,348 respectively, pursuant to a Share Purchase Agreement dated 01 March 2026.

On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has considered restructured compensation of its employees with effect from 01 April 2026 and assessed the impact of the changes, consistent with the Labour Codes, draft rules, FAQs and legal opinion. The Company based on the evaluation of the labour code has concluded that these changes do not have any material impact on the Company's Consolidated Financial Results. In case of any further clarification from the Government on other aspects of the New Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods on the Consolidated Financial Results.

13. Contingencies

During the year, the Company received a draft transfer pricing order dated 18 March 2026 pertaining to Assessment Year 2023-24, issued by the Transfer Pricing Officer under the provisions of the Income tax Act, 1961, proposing adjustments to the Company's returned income in respect of international transactions with associated enterprises. The proposed transfer pricing adjustment in the draft order aggregates to ₹ 1,114, the amount of tax demand will be as per the final order which is not received as on date. The Company has exercised its option to seek resolution of the proposed adjustment through the Mutual Agreement Procedure (MAP) in accordance with the applicable tax treaty provisions between India and the relevant treaty jurisdiction(s). The MAP application has been filed within the prescribed timelines.

Based on Management's assessment, supported by external tax advice, and considering the merits of the case, including the Company's transfer pricing documentation, economic analyses, and relevant judicial precedents, management believes that the matter is effectively contestable and that it is not probable that an outflow of resources will be required to settle the obligation. Accordingly, no provision has been recognised in the financial statements as at the reporting date, and the proposed exposure has been disclosed as a contingent liability, pending resolution under the MAP process.

13
INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Statement of Consolidated Cash Flow

(All amounts in ₹ millions)

Particulars	Year ended
	31 March 2026	31 March 2025
	Audited	Audited
A. Cash flows from operating activities
Profit before tax for the period	5,250	5,393
Adjustments to reconcile profit for the year to net cash generated from operating activities:
Depreciation and amortisation expense	1,265	802
Finance costs	159	194
Gain due to change in contingent consideration	-	(162)
Exceptional items - Provision for litigation expenses	203	-
Interest income and dividend income	(363)	(501)
Loss allowance on loan	-	135
Net gain on disposal / fair valuation of investments	(300)	(292)
Gain on termination of lease	(9)	-
Loss on sale of fixed assets	(1)	-
Bad debts written off	8	-
Expected credit loss provision / (reversal) on trade receivables and advances	-	18
Equity settled share based payment expense	256	174
Effect of exchange loss / (gain) on restatement of monetary assets and liabilities	54	17
Operating profit before working capital changes	6,522	5,778
Movements in working capital:
(Increase)/decrease in trade receivables	35	(820)
(Increase)/ decrease in loans and advances and other assets	(231)	343
Increase in liabilities	1,437	611
Increase in provisions	221	107
Cash generated from operating activities	7,984	6,019
Income tax paid (net)	(1,476)	(1,600)
Net cash generated from operating activities (A)	6,508	4,419
B. Cash flows from investing activities
Purchase of property, plant and equipment	(443)	(300)
Interest received	126	486
Payment for acquisition of business, net of cash acquired	(7,235)	(1,113)
Purchase of Investments accounted for using the FVTPL	(35,616)	(52,572)
Redemption of Investments	38,090	47,932
Investment in fixed deposit	(3,663)	(18,168)
Redemption / maturity of fixed deposit	3,617	16,908
Net cash used in investing activities (B)	(5,124)	(6,827)
C. Cash flows from financing activities
Proceeds from fresh issue of equity shares (net of share issue expense)	53	7,327
Interest and finance charges paid	-	(103)
Payment of lease liabilities	(399)	(318)
Dividend Paid	(480)	-
Repayment of borrowings	-	(4,031)
Net cash generated / (used) in from financing activities (C)	(826)	2,875
Net increase in cash and cash equivalents (A+B+C)	558	467
Cash and cash equivalents at the beginning of the year	2,410	1,886
Effect of exchange differences on translation of foreign currency cash and cash equivalents	40	57
Cash and cash equivalents at the end of the year	3,008	2,410

For the purpose of the statement of cash flow, cash and cash equivalents comprise the following:

Particulars	As at
	31 March 2026	31 March 2025
	Audited	Audited
Cash in hand	-	-
Balances with banks:
- In current accounts	2,258	1,503
- In deposit accounts	750	907
Total	3,008	2,410

See accompanying notes to the Consolidated Financial Results

INDEGENE LIMITED

INDEGENE LIMITED
CIN No. L73100KA1998PLC102040
Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

14 Segment information

Effective 01 October 2025, the Group has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the Chief operating decision maker reviews and evaluates performance of the business of the Group. Pursuant to the above, in accordance with the requirement specified in Ind AS 108, the comparative period information has been recasted to give the effect of this change.

Subsequent to the above change the Group will now have only 2 reportable segment i.e., Enterprise Commercial Solutions and Enterprise Medical Solutions.

Segment wise revenue and results are as follows:

Particulars	Quarter ended			Year ended
	31 March	31 December	31 March	31 March	31 March
	2026	2025	2025	2026	2025
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Segment revenue
Enterprise Medical Solutions	2,537	2,387	2,107	9,298	8,025
Enterprise Commercial Solutions	7,193	6,689	5,222	24,605	19,348
Others*	304	345	227	1,202	1,020
Total	10,034	9,421	7,556	35,105	28,393
2. Segment results
Enterprise Medical Solutions	672	612	585	2,435	2,081
Enterprise Commercial Solutions	1,212	1,199	1,062	4,492	3,942
Others*	(163)	(55)	(100)	(327)	(329)
Total	1,721	1,756	1,547	6,600	5,694
Unallocable expenses	(85)	(161)	(72)	(410)	(351)
Depreciation and amortisation expense	(418)	(396)	(207)	(1,264)	(802)
Other income (net)	107	194	256	720	1,072
Finance cost	(71)	(46)	(31)	(193)	(220)
Exceptional item	(205)	-	-	(203)	-
Tax expense	(254)	(318)	(317)	(1,239)	(1,326)
Profit after Tax	797	1,029	1,176	4,011	4,067

*Others mainly comprises of consultancy and clinical business.

Notes on Segment information

Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

The Board of Directors, in its meeting on 29 April 2026, have proposed a final dividend of ₹2.25 per equity shares for the financial year ended 31 March 2026. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved, would result in a cash outflow of approximately ₹542.

Bengaluru
29 April 2026

Chief Executive Officer and Executive Director

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High
Grounds, Bengaluru - 560 001
Karnataka, India
Tel: +91 (80) 6188 6000
Fax: +91 (80) 6188 6011

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2026 of INDEGENE LIMITED (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026.

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

Deloitte Haskins & Sells

together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026, has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Page 2 of 4

Deloitte Haskins & Sells

Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities or business activities included in the Annual Standalone Financial Results of which we are the independent auditors. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings

Page 3 of 4

Deloitte Haskins & Sells

including any significant deficiencies in internal control that we identify during our audit.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of this matter.

Reporting on comparatives reviewed/ audited by the predecessor auditor

The standalone financial results of the Company for the quarter and year ended March 31, 2025 included in the Statement, were reviewed/audited by the predecessor auditor who expressed an unmodified conclusion and opinion on those financial results on April 28, 2025.

Our report on the Statement is not modified in respect of this matter.

For Deloitte Haskins & Sells
Chartered Accountants
Firm's Registration No. 008072S

Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920VUSJAM5803

Place: Bengaluru
Date: April 29, 2026

Page 4 of 4

Indegene Limited

CIN No. L73100KA1998PLC102040

Statement of Standalone Financial Results for the quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Year ended	Year ended
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		Unaudited
(Refer note 2)	Unaudited	Unaudited
(Refer note 2)	Audited	Audited
1	Income
	(a) Revenue from operations	3,682	2,901	2,667	12,206	10,936
	(b) Other income (net)	61	226	352	783	904
	Total income	3,743	3,127	3,019	12,989	11,840
2	Expenses
	(a) Employee benefits expense	2,134	2,019	1,845	7,952	7,592
	(b) Finance costs	31	18	15	87	62
	(c) Depreciation and amortisation expense	109	95	69	363	262
	(d) Other expenses	517	505	426	1,773	1,539
	Total expenses	2,791	2,637	2,355	10,175	9,455
3	Profit before tax (1-2)	952	490	664	2,814	2,385
4	Tax expense
	- Current tax	260	129	174	707	630
	- Deferred tax	(29)	13	(52)	(12)	(58)
	Total tax expense	231	142	122	695	572
5	Profit for the period/year (3-4)	721	348	542	2,119	1,813
6	Other Comprehensive Income (OCI), net of taxes
	Items that will not be reclassified subsequently to the statement of profit or loss:
	Remeasurement of defined benefit obligation	(1)	6	(39)	41	(21)
	Deferred tax relating to items that will not be reclassified to profit and loss	1	(1)	10	(10)	5
	Items that will be reclassified subsequently to profit or loss:
	Exchange differences on translating the financial statements of foreign operation	-	-	5	-	3
	Net change in fair value of forward contracts designated as cash flow hedges	(79)	-	-	(79)	-
	Deferred tax relating to items that will be classified to profit and loss	20	-	-	20	-
	Total Other Comprehensive (Loss)/Income for the period/year (net of tax)	(59)	5	(24)	(28)	(13)
7	Total comprehensive income for the period/year (5+6)	662	353	518	2,091	1,800
8	Paid-up equity share capital (Face value of ₹ 2 each)	481	480	479	481	479
9	Other equity				20,324	18,403
10	Earning per equity share (face value ₹ 2 each)*
	(a) Basic (in ₹)	3.00	1.45	2.26	8.83	7.64
	(b) Diluted (in ₹)	2.98	1.44	2.25	8.78	7.59

*Earnings per share is not annualised for quarter ended.

See accompanying notes to the Standalone financial results

GENF

Indegene Limited

CIN No. L73100KA1998PLC102040

Statement of Standalone Assets and Liabilities

(All amounts in ₹ millions, except share data and where otherwise stated)

| | Particulars | As at
31 March 2026 | As at
31 March 2025 |
| --- | --- | --- | --- |
| | | Audited | Audited |
| A | ASSETS | | |
| I | Non-current assets | | |
| | (a) Property, plant and equipment | 453 | 285 |
| | (b) Capital work-in-progress | 118 | 36 |
| | (c) Right-of-use assets | 673 | 243 |
| | (d) Financial assets | | |
| | (i) Investments | 6,166 | 4,713 |
| | (ii) Loan | 3,550 | 3,635 |
| | (iii) Other financial assets | 693 | 83 |
| | (e) Deferred tax assets (net) | 238 | 216 |
| | (f) Non-current tax assets (net) | 172 | 102 |
| | (g) Other non-current assets | 7 | 4 |
| | Total non-current assets | 12,070 | 9,317 |
| II | Current assets | | |
| | (a) Financial assets | | |
| | (i) Investments | 7,016 | 5,033 |
| | (ii) Loan | 443 | 408 |
| | (iii) Trade receivables | | |
| | Billed | 2,834 | 4,105 |
| | Unbilled | 50 | 79 |
| | (iv) Cash and cash equivalents | 485 | 352 |
| | (v) Other bank balances | 811 | 1,284 |
| | (vi) Other financial assets | 291 | 323 |
| | (b) Other current assets | 819 | 596 |
| | Total current assets | 12,749 | 12,180 |
| | Total assets | 24,819 | 21,497 |
| B | EQUITY AND LIABILITIES | | |
| 1 | Equity | | |
| | (a) Equity share capital | 481 | 479 |
| | (b) Other equity | 20,324 | 18,403 |
| | Total equity | 20,805 | 18,882 |
| 2 | Liabilities | | |
| 1 | Non-current liabilities | | |
| | (a) Financial liabilities | | |
| | (i) Lease liabilities | 480 | 135 |
| | (ii) Other financial liabilities | 139 | - |
| | (b) Provisions | 657 | 585 |
| | Total non-current liabilities | 1,276 | 720 |
| II | Current liabilities | | |
| | (a) Financial liabilities | | |
| | (i) Lease liabilities | 218 | 137 |
| | (ii) Trade payables | | |
| | Total outstanding dues of micro enterprises and small enterprises and | 26 | 17 |
| | Total outstanding dues of creditors other than micro enterprises and small enterprises | 300 | 331 |
| | (iii) Other financial liabilities | 1,078 | 700 |
| | (b) Other current liabilities | 272 | 230 |
| | (c) Provisions | 534 | 469 |
| | (d) Current tax liabilities (net) | 310 | 11 |
| | Total current liabilities | 2,738 | 1,895 |
| | Total liabilities | 4,014 | 2,615 |
| | Total equity and liabilities | 24,819 | 21,497 |

See accompanying notes to the Standalone financial results

LIDGENE

Indegene Limited

CIN No.1.73100KA1998PLC102040

Statement of Standalone Cash Flow

(All amounts in ₹ millions, except share data and where otherwise stated)

Particulars	For the year ended	For the year ended
	31 March 2026	31 March 2025
	Audited	Audited
A. Cash flows from operating activities
Profit before tax for the period	2,814	2,385
Adjustments to reconcile profit for the year to net cash generated from operating activities:
Depreciation and amortization expense	363	262
Finance costs	79	58
Interest income	(444)	(464)
Net gain on disposal / fair valuation of investments	(300)	(292)
Gain on termination of lease	(9)	-
Expected credit loss provision on trade receivables and advances	(7)	3
Equity settled share based payment expenses	84	74
Reversals of provision for diminution in value of loans and interest	(3)	(5)
Net gain on sale of investments in subsidiaries	-	(36)
Effect of exchange differences on restatement	79	(3)
Operating profit before working capital changes	2,656	1,982
Movements in working capital:
(Increase)/decrease in trade receivables	1,396	(428)
(Increase)/decrease in loans and advances and other assets	(174)	521
Increase/ (decrease) in liabilities	(78)	(236)
Increase/ (decrease) in provisions	135	157
Cash generated from operating activities	3,935	1,996
Income taxes paid	(479)	(706)
Net cash generated from operating activities (A)	3,456	1,290
B. Cash flows from investing activities
Purchase of property, plant and equipment	(441)	(165)
Interest received	497	306
Proceeds from repayments of related party loan	411	2
Loan to Subsidiaries	-	(3,950)
Investment in subsidiary	(1,453)	(953)
Proceeds from sale of investments in subsidiaries	-	130
Purchase of Investments accounted for using the FVTPL	(4,440)	(6,024)
Redemption of Investments	2,757	3,667
Investment in fixed deposit	(3,669)	(18,168)
Redemption / maturity of fixed deposit	3,617	16,908
Net cash (used) in investing activities (B)	(2,721)	(8,247)
C. Cash flows from financing activities
Proceeds from fresh issue of equity shares (net of share issue expense)	53	7,328
Dividend paid	(480)	-
Payment of lease liabilities	(199)	(155)
Net cash generated/(used) in financing activities (C)	(626)	7,173
Net increase/(decrease) in cash and cash equivalents (A+B+C)	109	216
Cash and cash equivalents at the beginning of the year	352	132
Effect of exchange differences on translation of foreign currency cash and cash equivalents	24	4
Cash and cash equivalents at the end of the year	485	352

For the purpose of the statement of cash flows, cash and cash equivalents comprise the following :

| Particulars | As at
31 March 2026 | As at
31 March 2025 |
| --- | --- | --- |
| Cash in hand | - | - |
| Balances with bank: | | |
| - In current accounts | 170 | 352 |
| - In deposit accounts with original maturity less than 3 months | 315 | - |
| Total | 485 | 352 |

See accompanying notes to the Standalone financial results

SECRET

Indegene Limited
CIN No. L73100KA1998PLC102040
Notes to the Statement of Standalone Financial Results for quarter and year ended 31 March 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

The above Standalone Financial Results of the Indegene Limited ("the Company"), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. *** in the financial information denote amounts less than ₹ 0.50 million.
The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 April 2026 and approved by the Board of Directors at its meeting held on 29 April 2026. The figures for the quarter ended 31 March 2026 and 31 March 2025, are the balancing figures between audited figures in respect of full financial year and published unaudited year to date figures up to the end of the third quarter of the current and previous financial year respectively, which were subject to limited review.
The Standalone Financial Results for the quarter and year ended 31 March 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
During the year ended 31 March 2025, the Company had completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹ 2 each at an issue price of ₹452 per share (Issue price of ₹422, including a share premium of ₹420 per share, for employee quota towards fresh issue), comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company has received an amount of ₹7,246(1) (net of Company's share of IPO expenses of ₹354, retained in the Public Offer Account to the extent unpaid) from the proceeds of the fresh issue. Out of the Company's shares of IPO expenses ₹319 has been adjusted to securities premium.

The utilization of IPO proceeds of ₹7,246(1) is summarized below:

Particulars	Amount to be utilised as per offer document (1)	Amount utilized up to 31 March 2026	Amount unutilized as of 31 March 2026
Repayment/prepayment of indebtedness of one of the Material Subsidiary, ILSL Holdings, Inc. (2)	3,950	3,950	-
Funding the capital expenditure requirements of the Company and one of the Material Subsidiary	644	577	67
Technology, Cybersecurity and Cloud infrastructure related cost (1)	350	253	97
General corporate purposes and inorganic growth	2,302	2,294	8
Total	7,246	7,074	172

On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has considered restructured compensation of its employees with effect from 01 April 2026 and assessed the impact of the changes, consistent with the Labour Codes, draft rules, FAQs and legal opinion. The Company based on the evaluation of the labour code has concluded that these changes do not have any material impact on the Company's Financial Statements. In case of any further clarification from the Government on other aspects of the New Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods on the Financial Statements.

B
18
AGREEMENT

7 During the year ended 31 March 2026, 613,772 options have been granted under Employee Restricted Stock Unit plan 2020 ('RSU 2020'), 318,251 options have been granted under Employee Stock Option Plan 2020 ('ESOP 2020') and 56,462 options have been granted under Company Share Option Plan 2022 ('CSOP 2022') to the eligible employee of the Company. 670,418 options under RSU 2020 plan, 215,192 options under ESOP 2020 plan and 7,782 options under ESOP 2020 plan have been exercised during the year.

8 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.

9 Contingencies

Based on management's assessment, supported by external tax advice, and considering the merits of the case, including the Company's transfer pricing documentation, economic analyses, and relevant judicial precedents, management believes that the matter is effectively contestable and that it is not probable that an outflow of resources will be required to settle the obligation. Accordingly, no provision has been recognised in the financial statements as at the reporting date, and the proposed exposure has been disclosed as a contingent liability, pending resolution under the MAP process.

10 The Board of Directors, in its meeting on 29 April 2026, have proposed a final dividend of ₹2.25 per equity shares for the financial year ended 31 March 2026. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved, would result in a cash outflow of approximately ₹542.

Bengaluru
29 April 2026

Date:– April 29, 2026

The Declaration by CFO regarding audit report with unmodified opinion

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors Deloitte Haskins & Sells, Chartered Accountants, Firm Registration No. 008072S Chartered Accountants, have submitted an unmodified opinion / unqualified opinion on the audited Financial Results for the year and quarter ended 31st March 2026.

For Indegene Limited

Suhas Prabhu
Chief Financial Officer

indegene

Registered office

Indegene Limited,
Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

AI assistant

Indegene Limited Audit Report / Information 2026

59309_rns_2026-04-29_86574d40-3eee-4db8-a249-f1cd7aaa2ad2.pdf

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

Opinion and Conclusion

(a) Opinion on Annual Consolidated Financial Results

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

Deloitte Haskins & Sells

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

Management's and Board of Directors' Responsibilities for the Statement

Deloitte Haskins & Sells

Auditor’s Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026.

Deloitte Haskins & Sells

Other Matters

Reporting on comparatives reviewed/ audited by the predecessor auditor

Deloitte Haskins & Sells

7. Acquisition of Biopharm Parent Holdings Inc.:

The following table presents the allocation of purchase price:

8. Acquisition of Warn & Co Limited:

9. Acquisition of Cake Kommunikations Holdings GmbH:

10. Exceptional item: Litigation expenses

13. Contingencies

14 Segment information

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

Opinion and Conclusion

(a) Opinion on Annual Standalone Financial Results

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

Management's and Board of Directors' Responsibilities for the Statement

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Deloitte Haskins & Sells

The Declaration by CFO regarding audit report with unmodified opinion

AI assistant

Indegene Limited — Audit Report / Information 2026

59309_rns_2026-04-29_86574d40-3eee-4db8-a249-f1cd7aaa2ad2.pdf

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

Opinion and Conclusion

(a) Opinion on Annual Consolidated Financial Results

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

Deloitte Haskins & Sells

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

Management's and Board of Directors' Responsibilities for the Statement

Deloitte Haskins & Sells

Auditor’s Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026.

Deloitte Haskins & Sells

Other Matters

Reporting on comparatives reviewed/ audited by the predecessor auditor

Deloitte Haskins & Sells

7. Acquisition of Biopharm Parent Holdings Inc.:

The following table presents the allocation of purchase price:

8. Acquisition of Warn & Co Limited:

9. Acquisition of Cake Kommunikations Holdings GmbH:

10. Exceptional item: Litigation expenses

13. Contingencies

14 Segment information

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

Opinion and Conclusion

(a) Opinion on Annual Standalone Financial Results

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

Management's and Board of Directors' Responsibilities for the Statement

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Deloitte Haskins & Sells

The Declaration by CFO regarding audit report with unmodified opinion

More from Indegene Limited

Indegene Limited Audit Report / Information 2026